Related Experiment Video
Updated: Oct 25, 2025

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
Lynch syndrome: further defining the pediatric spectrum
Chelsea Self1, Alexandra Suttman2, Kami Wolfe Schneider2
1Center for Cancer and Blood Disorders, Department of Pediatrics, Lurie Children's Hospital, 225 E. Chicago Ave, Chicago, IL 60611, United States; Center for Cancer and Blood Disorders, Department of Pediatrics, Children's Hospital Colorado and University of Colorado, 13123 E. 16th Ave, Aurora, CO 80045, United States.
Abstract:
Lynch syndrome (LS) is an autosomal dominant cancer predisposition syndrome defined molecularly by the presence of a pathogenic heterozygous variant in one of the mismatch repair genes: MLH1, MSH2, MSH6, PMS2, or EPCAM. The incidence of LS in the general population is estimated at 1 in 279, with an even higher incidence in those with colorectal cancer and endometrial cancer, the two most common Lynch-associated cancers. Lynch syndrome is currently considered an "adult onset" cancer predisposition syndrome, with the majority of malignancies appearing in adulthood, and recommended screening beginning in adulthood. At present, expert guidelines discourage testing minors for Lynch syndrome. We report seven cases in which children presented with LS and pediatric malignancy, suggesting possible association of childhood onset of cancers with monoallelic mismatch repair deficiency.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Distribution
Sex-linked Disorders
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pleiotropy
